MDT-Based Comprehensive Management of Type 3 Von Willebrand Disease in Pregnancy: From Preimplantation Genetic Testing to Antenatal Care, Delivery and Postpartum Period

Why It Matters

Safe peripartum management of type 3 von Willebrand disease expands treatment options for rare bleeding disorders, reducing maternal and neonatal risk and guiding obstetric protocols worldwide.

Key Takeaways

• First Chinese peripartum use of recombinant von Willebrand factor.
• Target‑guided dosing achieved ≥30% VWF before amniocentesis.
• Multidisciplinary team coordinated care throughout pregnancy and delivery.
• Caesarean blood loss limited to 400 mL, no hemorrhagic complications.
• Strategy offers template for managing severe bleeding disorders in obstetrics.

Pulse Analysis

Type 3 von Willebrand disease (VWD) is the most severe form of the common inherited bleeding disorder, characterized by virtually absent von Willebrand factor and markedly low factor VIII. While normal pregnancy triggers a natural rise in coagulation proteins, patients with type 3 VWD do not experience this protective surge, leaving them vulnerable to life‑threatening hemorrhage during invasive obstetric procedures. Historically, management has relied on plasma‑derived concentrates, which carry infection risk and variable purity. The advent of recombinant von Willebrand factor (rVWF) offers a pathogen‑free, precisely dosed alternative, yet clinical experience in the peripartum setting remains limited, especially outside Western markets.

The reported case follows a 36‑year‑old Chinese woman with type 3 VWD who achieved pregnancy through in‑vitro fertilisation. A multidisciplinary team—including hematologists, maternal‑fetal medicine specialists, anesthesiologists and laboratory scientists—implemented a target‑guided protocol, administering rVWF to reach a pre‑procedure activity of ≥30 % before amniocentesis and ≥50 % before a scheduled caesarean section. Real‑time factor assays guided dosing, and supplemental factor VIII was added as needed. The delivery proceeded with an estimated 400 mL blood loss and no maternal or neonatal bleeding, marking the first documented peripartum use of rVWF in China.

This successful outcome underscores the value of precision medicine and coordinated care for rare bleeding disorders in obstetrics. By demonstrating that laboratory‑driven dosing can achieve hemostatic targets without excess transfusion, the case provides a practical template for hospitals adopting rVWF, a product projected to grow in the global hemostasis market as clinicians seek safer alternatives to plasma‑derived therapies. Guidelines may soon incorporate target‑guided rVWF strategies for high‑risk pregnancies, prompting further research into optimal activity thresholds and cost‑effectiveness. Ultimately, the approach promises to improve maternal‑fetal safety and expand therapeutic options for patients with severe VWD.